Abstract
Vaccines that target the preerythrocytic phase of malaria hold great promise as elimination tools since they are the sole vaccines that can achieve sterile protection against a challenge. This chapter focuses on preerythrocytic stage vaccines based on live attenuated parasites. It first summarizes the main conclusions that have emerged from studies in rodents, which compared various parasite attenuation methods, and then presents the vaccination regimens that are currently being tested in humans.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ewer KJ, Sierra-Davidson K, Salman AM et al (2015) Progress with viral vectored malaria vaccines: a multi-stage approach involving ‘unnatural immunity. Vaccine 33:7444–7451
Nussenzweig RS, Vanderberg J, Most H et al (1967) Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216:161–163
Tse SW, Radtke AJ, Zavala F (2011) Induction and maintenance of protective CD8+ T cells against malaria liver stages: implications for vaccine development. Mem Inst Oswaldo Cruz 106(Suppl 1):172–178
Beaudoin RL, Strome CP, Mitchell F et al (1977) Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 42:1–5
Friesen J, Silvie O, Putrianti ED et al (2010) Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2:40ra49
Orjih AU, Nussenzweig RS (1979) Plasmodium berghei: suppression of antibody response to sporozoite stage by acute blood stage infection. Clin Exp Immunol 38:1–8
Nganou-Makamdop K, Sauerwein RW (2013) Liver or blood-stage arrest during malaria sporozoite immunization: the later the better? Trends Parasitol 29:304–310
Mueller AK, Labaeid M, Kappe SH et al (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433:164–167
Bijker EM, Borrmann S, Kappe SH et al (2015) Novel approaches to whole sporozoite vaccination against malaria. Vaccine 33:7462–7468
Butler NS, Schmidt NW, Vaughan AM et al (2011) Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9:451–462
Clyde DF, Most H, McCarthy VC et al (1973) Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 266:169–177
Spring M, Murphy J, Nielsen R et al (2013) First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31:4975–4983
Roestenberg M, McCall M, Hopman J et al (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361:468–477
Roestenberg M, Teirlinck AC, McCall MB et al (2011) Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377:1770–1776
Bijker EM, Bastiaens GJ, Teirlinck AC et al (2013) Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A 110:7862–7867
Bijker EM, Schats R, Obiero JM et al (2014) Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. PLoS One 9:e112910
Luke TC, Hoffman SL (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206:3803–3808
Hoffman SL, Billingsley PF, James E et al (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6:97–106
Epstein JE, Tewari K, Lyke KE et al (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334:475–480
Seder RA, Chang LJ, Enama ME et al (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359–1365
Ishizuka AS, Lyke KE, DeZure A et al (2016) Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med 22:614–623
Mordmüller B, Surat G, Lagler H et al (2017) Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542:445–449
Epstein JE, Paolino KM, Richie TL et al (2017) Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2:e89154
Lyke KE, Ishizuka AS, Berry AA et al (2017) Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A 114:2711–2716
Olutu A, Urbano V, Hamad A et al (2018) Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of PfSPZ vaccine for malaria in healthy Equatoguinean men. Am J Trop Med Hyg 98:308–318
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Mac-Daniel, L., Ménard, R. (2019). Live Vaccines Against Plasmodium Preerythrocytic Stages. In: Ariey, F., Gay, F., Ménard, R. (eds) Malaria Control and Elimination. Methods in Molecular Biology, vol 2013. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9550-9_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9550-9_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9549-3
Online ISBN: 978-1-4939-9550-9
eBook Packages: Springer Protocols